Login to Your Account



Chelsea Focuses on Northera; Drops CH-4051 on Phase II Miss

By Catherine Shaffer
Staff Writer

Friday, June 1, 2012
A Phase II trial of CH-4051, a product in development for rheumatoid arthritis (RA) from Chelsea Therapeutics Inc., failed to meet its primary endpoint of superiority over methotrexate.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription